Comparative efficacy and safety of Chinese herbal medicine for knee osteoarthritis: A protocol for systematic review and network meta-analysis

• Published in: Medicine (Baltimore) 2021-07, Vol.100 (29), p.e26671-e26671
• Main Authors: Yang, Lei, Wu, Bo-yu, Ma, Lu, Li, Zheng-dong, Xiong, Hui
• Format: Article
• Language: English
• Subjects: Drugs, Chinese Herbal - adverse effects; Drugs, Chinese Herbal - therapeutic use; Humans; Meta-Analysis as Topic; Network Meta-Analysis; Osteoarthritis, Knee - drug therapy; Phytotherapy; Research Design; Study Protocol Systematic Review; Systematic Reviews as Topic
• ISSN: 0025-7974; 1536-5964
• DOI: 10.1097/MD.0000000000026671

Knee osteoarthritis (OA) is a major public health concern causing chronic disability as well as a substantial burden on health care and the economy. However, effective treatments for knee OA were still not available. Numerous clinical studies have suggested that Chinese herbal medicine (CHM) seems to be clinically effective in treating knee OA. Thus, this study aims to evaluate the efficacy and safety of CHM in the treatment of knee OA through a systematic review and network meta-analysis. A comprehensive search will be performed in PubMed, Cochrane Library, Embase, Web of Science, China National Knowledge Infrastructure, VIP Database, Wanfang Database, Chinese Biomedical Database, and 3 clinical trials registration websites, from the database inception to May 2021. Randomized controlled trials meeting the eligible criteria based on the PICOS framework will be included. All studies fulfilling the eligible criteria will be assessed for risk of bias using the Cochrane Collaboration's tool. The primary outcome will be the visual analog scale (VAS), Western Ontario and McMaster Universities Osteoarthritis Index, and total effective rate. The secondary outcome is the incidence of adverse events. Data analysis will be performed using Stata, Addis, and WinBUGS. This study will provide a reliable evidence to assess effectiveness and safety of CHM for knee OA, which may provide guidance for clinical practice. This study protocol has been registered on INPLASY202160060.